Harel Insurance Investments & Financial Services Ltd. Acquires Shares of 24,000 Pfizer Inc. $PFE

Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 24,000 shares of the biopharmaceutical company’s stock, valued at approximately $674,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. MASTERINVEST Kapitalanlage GmbH grew its stake in Pfizer by 23.9% in the first quarter. MASTERINVEST Kapitalanlage GmbH now owns 57,402 shares of the biopharmaceutical company’s stock valued at $1,612,000 after purchasing an additional 11,077 shares during the last quarter. Luts & Greenleigh Group Inc. purchased a new position in shares of Pfizer in the 1st quarter worth approximately $207,000. Sanctuary Advisors LLC raised its stake in shares of Pfizer by 6.3% during the 1st quarter. Sanctuary Advisors LLC now owns 1,013,675 shares of the biopharmaceutical company’s stock worth $28,464,000 after acquiring an additional 59,828 shares in the last quarter. Sterling Investment Advisors Ltd. raised its stake in shares of Pfizer by 27.9% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 124,752 shares of the biopharmaceutical company’s stock worth $3,503,000 after acquiring an additional 27,192 shares in the last quarter. Finally, Sigma Planning Corp lifted its position in Pfizer by 3.3% during the first quarter. Sigma Planning Corp now owns 171,573 shares of the biopharmaceutical company’s stock valued at $4,818,000 after acquiring an additional 5,500 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.3%

Shares of Pfizer stock opened at $25.13 on Friday. The firm’s 50 day simple moving average is $25.22 and its two-hundred day simple moving average is $26.18. The firm has a market capitalization of $143.24 billion, a price-to-earnings ratio of 19.19 and a beta of 0.35. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the previous year, the company earned $0.92 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is presently 131.30%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on PFE shares. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. CICC Research began coverage on Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. Citigroup boosted their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Finally, UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.50.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer received FDA approval for a Padcev plus Keytruda regimen in muscle-invasive bladder cancer, expanding use of the combination as a new treatment option and supporting the company’s oncology growth story. Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen
• Positive Sentiment: Analyst commentary remains constructive on Pfizer’s valuation, with some recent coverage suggesting the stock may still offer upside versus Wall Street targets despite recent weakness. Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
• Neutral Sentiment: Market commentary also says Pfizer’s shares are below key moving averages, reflecting a cautious technical setup as investors weigh fading COVID revenue against pipeline growth, acquisitions, and dividend support. Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
• Neutral Sentiment: Pfizer also faces a new patent dispute, as Arbutus Biopharma filed international lawsuits over lipid nanoparticle technology used in mRNA COVID-19 vaccines. The case adds legal overhang, though the financial impact is still uncertain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India due to supply challenges, which could weigh on near-term international product sales and signals execution issues in the supply chain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.